- Home
- Apac Viscosupplementation Market
APAC Viscosupplementation Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-563 | No of pages: 257 | Format:
Asia-Pacific viscosupplementation market is projected to register a substantial CAGR of 9.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2022 to 2029.
Market Segmentation:
Asia-Pacific Viscosupplementation Market, By Source (animal origin and non-animal origin), Age Group (geriatric and adults), Injection (single injection, three injections, and five injections), Molecular Weight (intermediate molecular weight, low molecular weight, and high molecular weight), End User (hospital, orthopedic clinics, ambulatory care centers, and others), Distribution Channel (direct tender and retail sales), Country(China, Japan, India, South Korea, Singapore, Thailand, Vietnam, Malaysia, Taiwan, Indonesia, Philippines, and Rest of Asia-Pacific) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the Asia-Pacific viscosupplementation market are:
Rising geriatric population
Increasing risk of osteoporosis and osteoarthritis
Market Segmentation:
Asia-Pacific viscosupplementation market is categorized into six notable segments, which are the source, age group, molecular weight, injection, end user, and distribution channel.
On the basis of source, the Asia Pacific viscosupplementation market is segmented into animal origin and non-animal origin
On the basis of molecular weight, the Asia Pacific viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight
On the basis of injection, the Asia Pacific viscosupplementation market is segmented into single injection, three injections, and five injections
On the basis of age group, the Asia Pacific viscosupplementation market is segmented into geriatric and adults
On the basis of end-user, the Asia Pacific viscosupplementation market is segmented into hospitals, orthopedic clinics, ambulatory care centers, and others
On the basis of distribution channel, the Asia Pacific viscosupplementation market is segmented into direct tender and retail sales
Market Players:
The key market players operating in the Asia-Pacific viscosupplementation market are listed below:
Anika Therapeutics, Inc.
SEIKAGAKU CORPORATION
Bioventus
Fidia Farmaceutici S.P.A
Ferring B.V
sanofi-aventis U.S. LLC
Zimmer Biomet
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 59
1.1 OBJECTIVES OF THE STUDY 59
1.2 MARKET DEFINITION 59
1.3 OVERVIEW OF ASIA PACIFIC VISCOSUPPLEMENTATION MARKET 59
1.4 CURRENCY AND PRICING 61
1.5 LIMITATIONS 61
1.6 MARKETS COVERED 62
2 MARKET SEGMENTATION 65
2.1 MARKETS COVERED 65
2.2 GEOGRAPHICAL SCOPE 66
2.3 YEARS CONSIDERED FOR THE STUDY 67
2.4 DBMR TRIPOD DATA VALIDATION MODEL 68
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 71
2.6 MULTIVARIATE MODELLING 72
2.7 MARKET APPLICATION COVERAGE GRID 73
2.8 SOURCE LIFELINE CURVE 74
2.9 DBMR MARKET POSITION GRID 75
2.10 VENDOR SHARE ANALYSIS 76
2.11 SECONDARY SOURCES 77
2.12 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHT 82
4.1 PESTEL 83
4.2 PORTER'S FIVE FORCES MODEL 84
5 EPIDEMIOLOGY 85
6 INDUSTRIAL INSIGHTS 86
7 PIPELINE ANALYSIS FOR ASIA PACIFIC VISCOSUPPLEMENTATION MARKET 88
8 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: REGULATIONS 89
9 MARKET OVERVIEW 92
9.1 DRIVERS 94
9.1.1 RISING GERIATRIC POPULATION 94
9.1.2 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS 94
9.1.3 TECHNOLOGICAL ADVANCEMENT IN VISCOSUPPLEMENTATION 95
9.1.4 LOW PRODUCTION COST OF VISCOSUPPLEMENTATION PRODUCTS 95
9.2 RESTRAINTS 95
9.2.1 LACK OF TECHNICAL EXPERTISE 95
9.2.2 PRODUCT RECALL PROCEDURES 96
9.2.3 LIMITED APPLICATIONS OF VISCOSUPPLEMENTATION 96
9.3 OPPORTUNITIES 96
9.3.1 SAFETY AND EFFECTIVENESS OF INTRA-ARTICULAR HYALURONIC ACID (IAHA) 96
9.3.2 RISING HEALTHCARE INFRASTRUCTURE 97
9.3.3 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES 97
9.3.4 INCREASING NUMBER OF JOINT REPLACEMENTS AND SPORTS ACCIDENT 98
9.4 CHALLENGES 98
9.4.1 STRINGENT GOVERNMENT POLICIES FOR THE USE OF VISCOSUPPLEMENTATION 98
9.4.2 SIDE-EFFECTS OF VISCOSUPPLEMENTATION 99
10 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY SOURCE 100
10.1 OVERVIEW 101
10.2 NON-ANIMAL ORIGIN 103
10.2.1 ORTHOVISC 105
10.2.2 EUFLEXXA 105
10.2.3 MONOVISC 105
10.2.4 DUROLANE 105
10.2.5 GEL-ONE 106
10.2.6 SUPARTZ 106
10.2.7 GELSYN-3 106
10.2.8 CINGAL 106
10.2.9 SULPLASYN 106
10.2.10 VISCOSEAL 106
10.2.11 OSTEONIL 106
10.2.12 OTHERS 106
10.3 ANIMAL ORIGIN 106
10.3.1 HYLAN G-F 20 107
10.3.2 SYNVIC ONE 108
10.3.3 SYNVIC 108
10.3.4 OTHERS 108
10.3.5 HYALURONANS 108
10.3.6 HYALGAN 109
10.3.7 OTHERS 109
11 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT 110
11.1 OVERVIEW 111
11.2 INTERMEDIATE MOLECULAR WEIGHT 113
11.2.1 ORTHOVISC 114
11.2.2 EUFLEXXA 114
11.2.3 MONOVISC 115
11.2.4 DUROLANE 115
11.2.5 VISCOSEAL 115
11.2.6 OSTEONIL 115
11.2.7 OTHERS 115
11.3 LOW MOLECULAR WEIGHT 115
11.3.1 HYLAGAN 116
11.3.2 SUPARTZ 116
11.3.3 GELSYN-3 116
11.3.4 CINGAL 116
11.3.5 SULPLASYN 117
11.3.6 OTHERS 117
11.4 HIGH MOLECULAR WEIGHT 117
11.4.1 SYNVIC ONE 118
11.4.2 SYNVIC 118
11.4.3 OTHERS 118
12 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY INJECTION 119
12.1 OVERVIEW 120
12.2 SINGLE INJECTION 122
12.3 THREE INJECTION 123
12.4 FIVE INJECTION 124
13 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY AGE GROUP 125
13.1 OVERVIEW 126
13.2 ADULTS 128
13.3 GERIATRIC 129
14 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY END USER 130
14.1 OVERVIEW 131
14.2 HOSPITALS 133
14.3 ORTHOPEDIC CLINICS 134
14.4 AMBULATORY CARE CENTERS 135
14.5 OTHERS 136
15 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL 137
15.1 OVERVIEW 138
15.2 RETAIL SALES 140
15.3 DIRECT TENDER 141
16 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET, BY REGION 142
16.1 ASIA-PACIFIC 143
16.1.1 CHINA 153
16.1.2 INDIA 158
16.1.3 JAPAN 163
16.1.4 AUSTRALIA 167
16.1.5 MALAYSIA 172
16.1.6 THAILAND 178
16.1.7 SINGAPORE 183
16.1.8 SOUTH KOREA 188
16.1.9 INDONESIA 193
16.1.10 PHILIPPINES 199
16.1.11 TAIWAN 205
16.1.12 VIETNAM 211
16.1.13 REST OF ASIA-PACIFIC 216
17 ASIA PACIFIC VISCOSUPPLEMENTATION MARKET: COMPANY LANDSCAPE 217
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 217
18 SWOT ANALYSIS 218
19 COMPANY PROFILE 219
19.1 JOHNSON & JOHNSON SERVICES, INC. 219
19.1.1 COMPANY SNAPSHOT 219
19.1.2 REVENUE ANALYSIS 219
19.1.3 COMPANY SHARE ANALYSIS 220
19.1.4 PRODUCT PORTFOLIO 220
19.1.5 RECENT DEVELOPMENTS 220
19.2 BIOVENTUS 221
19.2.1 COMPANY SNAPSHOT 221
19.2.2 REVENUE ANALYSIS 221
19.2.3 COMPANY SHARE ANALYSIS 222
19.2.4 PRODUCT PORTFOLIO 222
19.2.5 RECENT DEVELOPMENTS 223
19.3 FERRING B.V. 224
19.3.1 COMPANY SNAPSHOT 224
19.3.2 COMPANY SHARE ANALYSIS 224
19.3.3 PRODUCT PORTFOLIO 224
19.3.4 RECENT DEVELOPMENT 224
19.4 SANOFI-AVENTIS U.S. LLC 225
19.4.1 COMPANY SNAPSHOT 225
19.4.2 REVENUE ANALYSIS 225
19.4.3 COMPANY SHARE ANALYSIS 226
19.4.4 PRODUCT PORTFOLIO 226
19.4.5 RECENT DEVELOPMENTS 226
19.5 ZIMMER BIOMET 227
19.5.1 COMPANY SNAPSHOT 227
19.5.2 REVENUE ANALYSIS 227
19.5.3 COMPANY SHARE ANALYSIS 228
19.5.4 PRODUCT PORTFOLIO 228
19.5.5 RECENT DEVELOPMENTS 229
19.6 SEIKAGAKU CORPORATION 230
19.6.1 COMPANY SNAPSHOT 230
19.6.2 REVENUE ANALYSIS 230
19.6.3 PRODUCT PORTFOLIO 231
19.6.4 RECENT DEVELOPMENTS 231
19.7 ANIKA THERAPEUTICS, INC. 232
19.7.1 COMPANY SNAPSHOT 232
19.7.2 REVENUE ANALYSIS 232
19.7.3 PRODUCT PORTFOLIO 233
19.7.4 RECENT DEVELOPMENTS 233
19.8 FIDIA FARMACEUTICI S.P.A 234
19.8.1 COMPANY SNAPSHOT 234
19.8.2 REVENUE ANALYSIS 234
19.8.3 PRODUCT PORTFOLIO 234
19.8.4 RECENT DEVELOPMENT 235
19.9 APTISSEN 236
19.9.1 COMPANY SNAPSHOT 236
19.9.2 PRODUCT PORTFOLIO 236
19.9.3 RECENT DEVELOPMENT 236
19.10 IBSA INSTITUT BIOCHIMIQUE SA 237
19.10.1 COMPANY SNAPSHOT 237
19.10.2 PRODUCT PORTFOLIO 237
19.10.3 RECENT DEVELOPMENT 237
19.11 LG CHEM. 238
19.11.1 COMPANY SNAPSHOT 238
19.11.2 REVENUE ANALYSIS 238
19.11.3 PRODUCT PORTFOLIO 239
19.11.4 RECENT DEVELOPMENTS 239
19.12 LIFECORE (A SUBSIDIARY OF LANDEC CORPORATION) 240
19.12.1 COMPANY SNAPSHOT 240
19.12.2 REVENUE ANALYSIS 240
19.12.3 PRODUCT PORTFOLIO 241
19.12.4 RECENT DEVELOPMENTS 241
19.13 ORTHOGENRX, INC. (A SUBSIDIARY OF AVNS) 242
19.13.1 COMPANY SNAPSHOT 242
19.13.2 REVENUE ANALYSIS 242
19.13.3 PRODUCT PORTFOLIO 242
19.13.4 RECENT DEVELOPMENTS 243
19.14 ORTOBRAND INTERNATIONAL 244
19.14.1 COMPANY SNAPSHOT 244
19.14.2 PRODUCT PORTFOLIO 244
19.14.3 RECENT DEVELOPMENT 244
19.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. 245
19.15.1 COMPANY SNAPSHOT 245
19.15.2 REVENUE ANALYSIS 245
19.15.3 PRODUCT PORTFOLIO 246
19.15.4 RECENT DEVELOPMENTS 246
19.16 TRB CHEMEDICA SA 247
19.16.1 COMPANY SNAPSHOT 247
19.16.2 PRODUCT PORTFOLIO 247
19.16.3 RECENT DEVELOPMENTS 248
19.17 VIATRIS INC. 249
19.17.1 COMPANY SNAPSHOT 249
19.17.2 REVENUE ANALYSIS 249
19.17.3 PRODUCT PORTFOLIO 250
19.17.4 RECENT DEVELOPMENTS 250
19.18 VIRCHOW BIOTECH 251
19.18.1 COMPANY SNAPSHOT 251
19.18.2 PRODUCT PORTFOLIO 251
19.18.3 RECENT DEVELOPMENT 251
19.19 ZUVENTUS HEALTHCARE LTD. (A SUBSIDIARY OF EMCURE PHARMACEUTICALS) 252
19.19.1 COMPANY SNAPSHOT 252
19.19.2 REVENUE ANALYSIS 252
19.19.3 PRODUCT PORTFOLIO 253
19.19.4 RECENT DEVELOPMENT 253
20 QUESTIONNAIRE 254
21 RELATED REPORTS 257
Segmentation
Short Description
Asia Pacific viscosupplementation market, By Source (animal origin and non-animal origin), Age Group (geriatric and adults), Injection (single injection, three injections, and five injections), Molecular Weight (intermediate molecular weight, low molecular weight, and high molecular weight), End User (hospital, orthopedic clinics, ambulatory care centers, and others), Distribution Channel (direct tender and retail sales) Country(China, Japan, India, South Korea, Singapore, Thailand, Vietnam, Malaysia, Taiwan, Indonesia, Philippines, and Rest of Asia-Pacific) Industry Trends and Forecast to 2029.
Market Definition:
The development of the therapeutic paradigm viscosupplementation for long-lasting pain relief in human and animal joints with osteoarthritis or traumatic arthritis was based on the finding that in arthritic conditions, the average molecular weight and concentration of hyaluronan decreased. Consequently, the elastoviscous properties of the synovial fluid are substantially reduced. Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times greater concentration than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan used today for therapeutic purposes, the rheological properties (viscosity and elasticity) are low. Therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions. It has comparable rheological properties to the fluid found in young, healthy individuals. The clinical benefit of viscosupplementation is long-lasting pain relief in arthritic joints.
Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market.
Market Segmentation:
Asia Pacific viscosupplementation market is categorized into six notable segments: source, age group, molecular weight, injection, end user, and distribution channel.
On the basis of source, the Asia Pacific viscosupplementation market is segmented into the animal origin and non-animal origin. Animal origin is further segmented into by type, hyaluronans, by brands, hylan G-F 20, by brand, Synvisc, and Synvisc one. Hyaluronans, by brands, are further segmented into hyalgan. Non-animal origin is segmented into SULPLASYN, GEL ONE, ORTHOVISC, MONOVISC, OSTEONIL, VISCOSEAL, EUFLEXXA, DUROLANE, SUPARTZ, GELSYN-3, and CINGEAL. In 2022, the non-animal origin segment is expected to dominate the Asia Pacific viscosupplementation market due to the increased density of hyaluronic acid (HA). Also, it displays high resistance to intraarticular degradation
On the basis of age group, the Asia Pacific viscosupplementation market is segmented into geriatric and adults. In 2022, the geriatric segment is expected to dominate the Asia Pacific viscosupplementation market due to an increase in the population
On the basis of injection, the Asia Pacific viscosupplementation market is segmented into single injection, three injections, and five injections. In 2022, the single injection segment is expected to dominate the Asia Pacific viscosupplementation market due to high responsiveness levels to single-injection treatment and a more prominent inclination for the administration of osteoarthritis
On the basis of molecular weight, the Asia Pacific viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight. In 2022, the intermediate molecular weight segment is expected to dominate the Asia Pacific viscosupplementation market due to the molecular weight of hyaluronic acid having a major influence on its efficacy and safety for viscosupplementation in hip osteoarthritis
On the basis of end-user, the Asia Pacific viscosupplementation market is segmented into hospitals, orthopedic clinics, ambulatory care centers, and others. In 2022, the hospital segment is expected to dominate the Asia Pacific viscosupplementation market due to rising preferences among customers
On the basis of distribution channel, the Asia Pacific viscosupplementation market is segmented into direct tender and retail sales. In 2022, the direct tender segment is expected to dominate the Asia Pacific viscosupplementation market as it is most commonly used by research labs, pharmaceutical shops, and hospitals
Market Players
The key market players operating in the Asia Pacific viscosupplementation market are listed below:
Anika Therapeutics, Inc.
SEIKAGAKU CORPORATION
Bioventus
Fidia Farmaceutici S.P.A
Ferring B.V
sanofi-aventis U.S. LLC
Zimmer Biomet
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.